Re-Branding "Risk-Based Monitoring" - A Call for "Targeted Site Quality Management" - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
Re-Branding "Risk-Based Monitoring" - A Call for "Targeted Site Quality Management"

Source: Applied Clinical Trials

With all of the buzz and excitement around risk-based monitoring, one might expect that the broad adoption of this emerging clinical research paradigm is well under way. Those familiar with the often painfully slow pace of innovation in the area of clinical R&D, however, will not be surprised by the more sobering reality that only a modest number of clinical trials have adopted a risk-based approach to site monitoring to date.  Most organizations engaged in clinical research have been sitting on the edge of the risk-based monitoring pool, anxiously dipping their toes in the water but unwilling to dive in until enough others jump in first and confirm that the water is safe.  

As illustrated in the graph, the percentage of source document verification (SDV) coverage measured industry-wide is indeed trending downward, but only at a modest rate, from about 92 percent in 2008 to 84 percent in 2012. The data were compiled from the Medidata Insights Metrics Warehouse, which contains operational metrics from over 6,000 clinical trials contributed by more than 100 sponsor organizations. 

The concerns most commonly cited by organizations resisting the adoption of risk-based monitoring revolve around a perceived degradation in site and data quality, and a perceived increase in regulatory risk.  Yet, given the strong regulatory endorsements and the numerous positive arguments and evidence already brought to bear in support of risk-based monitoring, concerns about the approach are rapidly becoming less credible.  And unlike the painfully slow transition from paper case report forms to electronic data capture (EDC) during the previous decade, the technology required to enable successful execution of risk-based monitoring already exists and is readily available.

What remains, then, primarily amounts to a change management exercise – both within each organization and for the industry as a whole.  And what the industry calls this paradigm can directly affect acceptance and, ultimately, adoption.

While “risk-based monitoring” is an accurate descriptor of the underlying methodology, it also conveys a negative connotation for many in the clinical research community which reinforces their fundamental fears regarding increased regulatory risk and potential quality issues.  The phrase is often misconstrued as describing a paradigm that increases overall operational risk, paired with a methodology by which that increased risk can be managed.  This misperception is quite the opposite of what risk-based monitoring promises! 

Getting rid of the word “risk”, then, would be a step in the right direction.  “Targeted” appears to be an apt alternative, as it very accurately describes the methodology at work and also emphasizes the positive efficiency gains that will result from implementing the approach.  Thus, “targeted monitoring” as a label is already a significant improvement over “risk-based monitoring.”

Additional improvements can be considered as well. For instance, to many industry professionals, “monitoring” or “site monitoring” still conveys a traditional understanding of a site monitor’s role, focused primarily on frequent visits to investigative sites that involve exhaustive review of source documents, regulatory binders and investigational product reconciliation.  Replacing “monitoring” with the words “site quality management” will help move the focus away from the traditional role and towards the broader and more holistic monitoring approach that is encouraged in the new paradigm.  With “site quality management,” the role of the site monitor is implicitly elevated to a more strategic level, supported by centralized and remote monitoring. 

The recommendation here is to rebrand “risk-based monitoring” as “targeted site quality management.”  Whether the industry adopts this name or some alternate wording, the change management challenge associated with the approach will be greatly impacted by the language used! 

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
87%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
8%
View Results
Untitled Document
Source: Applied Clinical Trials,
Click here